SavedAdd your journal

Journals / Turkish Journal of Internal Medicine / 2026 / Volume: 4 Special Issue

Pembrolizumab Induced Hypothyroidism: A Case Report

Sidelya Ecem Yiğit(ACIBADEM ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-9961-4066
İffet Beril Gökmen(ACIBADEM UNIVERSITY, SCHOOL OF MEDICINE)0000-0003-4986-200X
Yıldız Okuturlar(ACIBADEM UNIVERSITY, SCHOOL OF MEDICINE)0000-0002-1994-0014
Pages
—
Publication Date
2022-04-01
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Herein, we presented a case of pembrolizumab induced hypothyroidism.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Immune checkpoint inhibitors inhibit the inhibitory mechanism on the immune system, their side effects may be autoimmune diseases that occur due to excessive immune response.
📊
Key Findings & Data:Pembrolizumab is an immune checkpoint inhibitor targeting PD-1.
💡
Conclusion & Impact:Herein, we presented a case of pembrolizumab induced hypothyroidism.
🔬Design:Case Report
📍Scope:Comprehensive Sample
⚙️Variables:Pembrolizumab · immune checkpoint inhibitors · lung cancer

Abstract

Immune checkpoint inhibitors inhibit the inhibitory mechanism on the immune system, their side effects may be autoimmune diseases that occur due to excessive immune response. Pembrolizumab is an immune checkpoint inhibitor targeting PD-1. The most common clinical presentations of thyroid injury induced by pembrolizumab are destructive thyroiditis and overt hypothyroidism. Herein, we presented a case of pembrolizumab induced hypothyroidism.

🔖

Cite This Article

Yiğit, S. E., Gökmen, İ. B., Okuturlar, Y. (2022). Pembrolizumab Induced Hypothyroidism: A Case Report. Turkish Journal of Internal Medicine, Volume: 4 Special Issue. https://doi.org/10.46310/tjim.1078792

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Alhamad EH, Cosgrove GP. Interstitial lung disease: the initial approach. Med Clin North Am. 2011 Nov;95(6):1071-93. doi: 10.1016/j.mcna.2011.08.008.
  2. Parekh M, Donuru A, Balasubramanya R, Kapur S. Review of the chest CT differential diagnosis of ground-glass opacities in the COVID era. Radiology. 2020 Dec;297(3):E289-E302. doi: 10.1148/radiol.2020202504.
  3. Lee EYP, Ng MY, Khong PL. COVID-19 pneumonia: what has CT taught us? Lancet Infect Dis. 2020 Apr;20(4):384-385. doi: 10.1016/S1473-3099(20)30134-1.
  4. Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012 May 31;13(1):39. doi: 10.1186/1465-9921-13-39.
  5. Murugan AK. mTOR: Role in cancer, metastasis and drug resistance. Semin Cancer Biol. 2019 Dec;59:92-111. doi: 10.1016/j. semcancer.2019.07.003.
  6. Leung EY, Askarian-Amiri M, Finlay GJ, Rewcastle GW, Baguley BC. Potentiation of growth inhibitory responses of the mTOR inhibitor everolimus by dual mTORC1/2 inhibitors in cultured breast cancer cell lines. PLoS One. 2015 Jul 6;10(7):e0131400. doi: 10.1371/journal.pone.0131400.
  7. Lopez P, Kohler S, Dimri S. Interstitial lung disease associated with mTOR inhibitors in solid organ transplant recipients: Results from a large phase iii clinical trial program of everolimus and review of the literature. J Transplant. 2014;2014:305931. doi: 10.1155/2014/305931.